332 related articles for article (PubMed ID: 27503198)
21. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
[TBL] [Abstract][Full Text] [Related]
22. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
Tam CS; Stilgenbauer S
Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
[TBL] [Abstract][Full Text] [Related]
23. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.
Zenz T; Kröber A; Scherer K; Häbe S; Bühler A; Benner A; Denzel T; Winkler D; Edelmann J; Schwänen C; Döhner H; Stilgenbauer S
Blood; 2008 Oct; 112(8):3322-9. PubMed ID: 18689542
[TBL] [Abstract][Full Text] [Related]
24. The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.
Gladstone DE; Blackford A; Cho E; Swinnen L; Kasamon Y; Gocke CD; Griffin CA; Bolaños-Meade J; Jones RJ
Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):132-7. PubMed ID: 22285608
[TBL] [Abstract][Full Text] [Related]
25. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations.
Rigolin GM; del Giudice I; Formigaro L; Saccenti E; Martinelli S; Cavallari M; Lista E; Tammiso E; Volta E; Lupini L; Bassi C; Bardi A; Sofritti O; Daghia G; Cavazzini F; Marinelli M; Tavolaro S; Guarini A; Negrini M; Foà R; Cuneo A
Genes Chromosomes Cancer; 2015 Dec; 54(12):818-26. PubMed ID: 26355802
[TBL] [Abstract][Full Text] [Related]
26. Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia.
Messmer BT; Nour-Omid TS; Ghia E; Sanchez AB; Kipps TJ
Leuk Res; 2011 Jul; 35(7):965-7. PubMed ID: 21570119
[TBL] [Abstract][Full Text] [Related]
27. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
Gonzalez D; Martinez P; Wade R; Hockley S; Oscier D; Matutes E; Dearden CE; Richards SM; Catovsky D; Morgan GJ
J Clin Oncol; 2011 Jun; 29(16):2223-9. PubMed ID: 21483000
[TBL] [Abstract][Full Text] [Related]
28. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
29. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
Chang H; Jiang AM; Qi CX
Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
[TBL] [Abstract][Full Text] [Related]
30. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
[TBL] [Abstract][Full Text] [Related]
31. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
Knittel G; Rehkämper T; Korovkina D; Liedgens P; Fritz C; Torgovnick A; Al-Baldawi Y; Al-Maarri M; Cun Y; Fedorchenko O; Riabinska A; Beleggia F; Nguyen PH; Wunderlich FT; Ortmann M; Montesinos-Rongen M; Tausch E; Stilgenbauer S; P Frenzel L; Herling M; Herling C; Bahlo J; Hallek M; Peifer M; Buettner R; Persigehl T; Reinhardt HC
Nat Commun; 2017 Jul; 8(1):153. PubMed ID: 28751718
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Montserrat E; Dreger P
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
34. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
[TBL] [Abstract][Full Text] [Related]
35. Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia.
Kuss BJ; Tam CS
Intern Med J; 2017 Dec; 47 Suppl 6():5-10. PubMed ID: 29250930
[TBL] [Abstract][Full Text] [Related]
36. Genetic landscape of ultra-stable chronic lymphocytic leukemia patients.
Raponi S; Del Giudice I; Marinelli M; Wang J; Cafforio L; Ilari C; Piciocchi A; Messina M; Bonina S; Tavolaro S; Bordyuh M; Mariglia P; Peragine N; Mauro FR; Chiaretti S; Molica S; Gentile M; Visentin A; Trentin L; Rigolin GM; Cuneo A; Diop F; Rossi D; Gaidano G; Guarini A; Rabadan R; Foà R
Ann Oncol; 2018 Apr; 29(4):966-972. PubMed ID: 29365086
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Tausch E; Schneider C; Robrecht S; Zhang C; Dolnik A; Bloehdorn J; Bahlo J; Al-Sawaf O; Ritgen M; Fink AM; Eichhorst B; Kreuzer KA; Tandon M; Humphrey K; Jiang Y; Schary W; Bullinger L; Mertens D; Lurà MP; Kneba M; Döhner H; Fischer K; Hallek M; Stilgenbauer S
Blood; 2020 Jun; 135(26):2402-2412. PubMed ID: 32206772
[TBL] [Abstract][Full Text] [Related]
38. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
Lee HJ; Gallardo M; Ma H; Zhang X; Larsson CA; Mejia A; Hornbaker MJ; Qi Y; Su X; Pageon LR; Quintas-Cardama A; Post SM
Blood Cancer J; 2016 Jun; 6(6):e434. PubMed ID: 27284738
[TBL] [Abstract][Full Text] [Related]
39. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.
Ouillette P; Saiya-Cork K; Seymour E; Li C; Shedden K; Malek SN
Clin Cancer Res; 2013 Jun; 19(11):2893-904. PubMed ID: 23620403
[TBL] [Abstract][Full Text] [Related]
40. Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21).
Burlet B; Ramla S; Fournier C; Abrey-Recalde MJ; Sauter C; Chrétien ML; Rossi C; Duffourd Y; Ragot S; Buriller C; Tournier B; Chapusot C; Nadal N; Racine J; Guy J; Bailly F; Martin L; Casasnovas O; Bastie JN; Caillot D; Albuisson J; Broccardo C; Thieblemont C; Delva L; Maynadié M; Aucagne R; Callanan MB
Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33608382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]